4g7xh22
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00014560)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
FCGR1A inhibitor
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109641 ↗
Also known as
- 4g7xh22
- 4g7xh22
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00014560 | Phase 1 | Sep 1, 2000 | Dartmouth University, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dartmouth University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
2 organizations
Page 1 / 1